Allakos slumps on anti-inflammatory treatment's mixed trial results

Allakos

09/09/2022 13:42

** Drug developer Allakos Inc's  ALLK.O  shares drop 21.5%
to $3.64 - biggest pct loser across U.S. stock exchanges
premarket
    ** Co says its drug candidate to treat patients with an
inflammatory disease in the digestive system demonstrates mixed
results in a late-stage study  urn:newsml:reuters.com:*:nGNX4KKpyR
    ** Trial meets co-primary goal of improvement in tissue
specimen following biopsy, another main goal of improvement in
symptoms was not statistically significant - co
    ** Co is currently not planning to conduct additional
studies 
    ** Up to Thursday's close, stock down ~53% YTD 

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))